Th17 cells: a prognostic marker for MS rebound after natalizumab cessation?
Background:Multiple sclerosis (MS) patients are at risk of renewed disease activity after discontinuing natalizumab (NAT) treatment.Objective:Assessing the implication of T helper 17 (Th17) cells in MS reactivation after NAT cessation.Methods:We monitored frequencies of Th17 cells and interleukin (I...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2017
|
| In: |
Multiple sclerosis journal
Year: 2016, Volume: 23, Issue: 1, Pages: 114-118 |
| ISSN: | 1477-0970 |
| DOI: | 10.1177/1352458516640609 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1177/1352458516640609 Verlag, Volltext: https://doi.org/10.1177/1352458516640609 
|
| Author Notes: | Jürgen Haas, Katharina Schneider, Alexander Schwarz, Mirjam Korporal-Kuhnke, Simon Faller, Felipe von Glehn, Sven Jarius, Brigitte Wildemann |
| Summary: | Background:Multiple sclerosis (MS) patients are at risk of renewed disease activity after discontinuing natalizumab (NAT) treatment.Objective:Assessing the implication of T helper 17 (Th17) cells in MS reactivation after NAT cessation.Methods:We monitored frequencies of Th17 cells and interleukin (IL)-17 cytokine levels in blood samples of 57 MS patients, without, during, and after NAT exposure.Results:Frequencies of both Th17 cells and, in part, also IL-17 levels, in peripheral blood increased under prolonged NAT therapy, returned to baseline after NAT withdrawal and became almost undetectable in blood samples of individuals who experienced relapses during the wash-out phase.Conclusion:Assessing the Th17-cell/IL-17 axis might help to predict rebound MS activity after NAT withdrawal. |
|---|---|
| Item Description: | First published March 21,2016 Gesehen am 30.08.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1477-0970 |
| DOI: | 10.1177/1352458516640609 |